ProQR reports positive Phase 1 data for RNA editing drug AX-0810

June 25, 2026 6:25 AM

ProQR Therapeutics N.V. (Nasdaq: PRQR) announced positive target engagement data from its ongoing Phase 1 clinical study of AX-0810, an ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found